Professor Kevin Mortimer says he was diagnosed with terminal prostate cancer at age 48 and was later disease-free after treatment with a newer drug. In his account, the diagnosis comes at a personally difficult time, which he frames as making the prognosis especially distressing for his family. He reports that about two years after starting the treatment, his condition improves to the point where he considers himself free of disease. While the personal outcome is presented positively, the article also raises concerns about how new prostate cancer treatments are provided through the NHS. It highlights what it describes as a “postcode lottery,” suggesting that access to the therapy can vary depending on where patients live and on local commissioning or prescribing decisions. The reporting focuses on Mortimer’s experience and the wider question of whether patients across England and the UK receive similar access to recently approved or emerging treatments. It does not provide additional clinical trial data or broader outcome statistics beyond Mortimer’s individual case.